Suppr超能文献

心得安在肝脾型血吸虫病患者体内的处置情况。

Propranolol disposition in patients with hepatosplenic schistosomiasis.

作者信息

Homeida M M, Ali H M, Arbab B M, Harron D W

机构信息

Department of Medicine, University of Khartoum, Sudan.

出版信息

Br J Clin Pharmacol. 1987 Sep;24(3):393-6. doi: 10.1111/j.1365-2125.1987.tb03187.x.

Abstract

Eight Sudanese patients with hepatosplenic schistosomiasis and seven Sudanese controls were administered a single oral dose of long acting (LA), propranolol 160 mg; blood propranolol levels were measured at regular intervals for 12 h using g.l.c. In patients with hepatosplenic schistosomiasis, propranolol blood concentrations were greater (P less than 0.05) at all time intervals, Cmax 63.5 (29-143) ng ml-1 (median and range) than controls Cmax 23 (12-37) ng ml-1. Median AUC0-12 was also greater (P less than 0.05) (533 and 218 ng ml-1 h respectively), tmax were not significantly different. In patients and controls prior to treatment, standing heart rate (77.5 (60-110), 72 (68-74) beats min-1) systolic (120 (105-150), 110 (100-120) mm Hg) and diastolic blood pressure (75 (60-90), 70 (60-80) mm Hg) were not significantly different. However following propranolol administration a reduction (P less than 0.05) occurred in both systolic (median 20 mm Hg) and diastolic (median 12.5 mm Hg) blood pressure in the patients compared with controls. Heart rate was reduced by a median of 10 beats min-1 in both groups. These observations indicate that propranolol bioavailability in patients with hepatosplenic schistosomiasis is increased possibly due to reduced presystemic extraction.

摘要

对8例患有肝脾血吸虫病的苏丹患者和7名苏丹对照者单次口服160mg长效普萘洛尔;使用气相色谱法在12小时内定期测量血中普萘洛尔水平。在患有肝脾血吸虫病的患者中,在所有时间间隔内,普萘洛尔血药浓度均更高(P<0.05),Cmax为63.5(29 - 143)ng/ml(中位数和范围),而对照者的Cmax为23(12 - 37)ng/ml。中位数AUC0 - 12也更高(P<0.05)(分别为533和218 ng/ml·h),tmax无显著差异。在治疗前,患者和对照者的静息心率(77.5(60 - 110),72(68 - 74)次/分钟)、收缩压(120(105 - 150),110(100 - 120)mmHg)和舒张压(75(60 - 90),70(60 - 80)mmHg)无显著差异。然而,与对照者相比,服用普萘洛尔后患者的收缩压(中位数20mmHg)和舒张压(中位数12.5mmHg)均出现降低(P<0.05)。两组的心率中位数均降低了10次/分钟。这些观察结果表明,肝脾血吸虫病患者中普萘洛尔的生物利用度增加,可能是由于首过消除减少所致。

相似文献

4
[Intestinal absorption in the hepatosplenic form of schistosomiasis mansoni].
Rev Hosp Clin Fac Med Sao Paulo. 1971 Apr;26(2):55-60.
7
Altered drug metabolism in hepatosplenic schistosomiasis.
Rev Inst Med Trop Sao Paulo. 1979 Sep-Oct;21(5):254-9.
9
Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis.
J Hepatol. 1992 May;15(1-2):35-9. doi: 10.1016/0168-8278(92)90008-d.
10
Serum trypsin in hepatosplenic schistosomiasis in the Sudan.
Trop Med Parasitol. 1990 Dec;41(4):441-2.

引用本文的文献

本文引用的文献

2
Hepatic schistosomiasis.肝血吸虫病
Hepatology. 1981 Nov-Dec;1(6):653-61. doi: 10.1002/hep.1840010615.
4
Hepatic disease and drug pharmacokinetics.肝脏疾病与药物药代动力学
Clin Pharmacokinet. 1980 Nov-Dec;5(6):528-47. doi: 10.2165/00003088-198005060-00002.
5
Calcium antagonists. Pharmacokinetic properties.钙拮抗剂。药代动力学特性。
Drugs. 1983 Feb;25(2):113-24. doi: 10.2165/00003495-198325020-00002.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验